文献速递自身免疫性与大疱性皮肤病

药物使用与大疱性类天疱疮的关联:系统评价与Meta分析

Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该系统评价与Meta分析纳入13项病例对照研究、1项队列研究和1项随机临床试验,共285 884名参与者,评估既往药物暴露与大疱性类天疱疮(BP)的关联。病例对照研究的Meta分析显示,醛固酮拮抗剂、二肽基肽酶4抑制剂、抗胆碱能药和多巴胺能药物的既往使用与BP显著相关。队列研究显示二肽基肽酶4抑制剂使用者BP风险增加,临床试验发现利格列汀组BP发生率高于安慰剂组。

要点

  • 醛固酮拮抗剂、DPP-4抑制剂、抗胆碱能药和多巴胺能药物与BP显著相关。
  • 高龄且伴有致残性神经系统疾病者属高危人群,应谨慎处方上述药物。
  • 临床遇BP患者应详细询问用药史,评估可疑药物。

核心结论

  • 醛固酮拮抗剂、二肽基肽酶4抑制剂、抗胆碱能药和多巴胺能药物与BP相关。

研究设计与样本

  • 系统评价与Meta分析,纳入13项病例对照研究、1项队列研究和1项随机临床试验,共285 884名参与者。
  • 检索PubMed、Cochrane Central Register of Controlled Trials和Embase,从建库至2020年2月20日。
  • 采用随机效应模型进行Meta分析,并遵循MOOSE指南。

主要发现

  • 病例对照研究的Meta分析显示,BP与既往使用醛固酮拮抗剂显著相关(合并OR,1.75;95% CI,1.28-2.40)。
  • BP与既往使用二肽基肽酶4抑制剂显著相关(合并OR,1.92;95% CI,1.55-2.38)。
  • BP与既往使用抗胆碱能药显著相关(合并OR,3.12;95% CI,1.54-6.33)。
  • BP与既往使用多巴胺能药物显著相关(合并OR,2.03;95% CI,1.34-3.05)。

临床怎么用

  • 对高龄且伴有致残性神经系统疾病的患者,应谨慎处方醛固酮拮抗剂、二肽基肽酶4抑制剂、抗胆碱能药和多巴胺能药物。
  • 临床怀疑BP时应详细询问既往用药史,评估药物暴露与BP的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association between the use of medications and the development of bullous pemphigoid (BP) is unclear. OBJECTIVE: To assess the associations between previous exposure to certain medications and BP. DATA SOURCES: For this systematic review and meta-analysis, PubMed, the Cochrane Central Register of Controlled Trials, and Embase were searched for relevant studies from inception to February 20, 2020. STUDY SELECTION: Case-control or cohort studies and randomized clinical trials that examined the odds or risk of BP in patients with previous medication use were included. No geographic or language limitations were imposed. DATA EXTRACTION AND SYNTHESIS: The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline was followed. The Newcastle-Ottawa Scale was used to evaluate the risk of bias of included observational studies; Cochrane Collaboration's tool was used for randomized clinical trials. Aggregate data were used to conduct a random-effects model meta-analysis if the included studies were sufficiently homogenous. Subgroup analyses were performed for use of various medications of the same category. MAIN OUTCOMES AND MEASURES: Odds ratio (OR), hazard ratio, and risk ratio of bullous pemphigoid in association with medication use. RESULTS: This meta-analysis included 13 case-control studies, 1 cohort study, and 1 randomized clinical trial with a total of 285 884 participants. The meta-analysis of case-control studies showed a significant association of BP with previous use of aldosterone antagonists (pooled OR, 1.75; 95% CI, 1.28-2.40), dipeptidyl peptidase 4 inhibitors (pooled OR, 1.92; 95% CI, 1.55-2.38), anticholinergics (pooled OR, 3.12; 95% CI, 1.54-6.33), and dopaminergic medications (pooled OR, 2.03; 95% CI, 1.34-3.05). One cohort study found an increased risk of BP among patients receiving dipeptidyl peptidase 4 inhibitors (hazard ratio, 2.38; 95% CI, 1.16-4.88; P = .02). One trial found a higher occurrence of BP in patients with diabetes receiving linagliptin (0.2% in diabetes group vs 0% in the placebo group). CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that aldosterone antagonists, dipeptidyl peptidase 4 inhibitors, anticholinergics, and dopaminergic medications are associated with BP. These medications should be judiciously prescribed, particularly in high-risk patients who are elderly and have disabling neurologic disorders.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu SD, Chen WT, Chi CC, et al. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020. PMID: 32584924. doi:10.1001/jamadermatol.2020.1587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。